Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 24, 2023 | Last Trade: US$ 0 0.00 0.00

FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that Mark Pomeranz, President and Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference.

H.C. Wainwright 25^th Annual Global Investment Conference
Presentation Date:	Monday, September 11, 2023 at 7:00 AM ET
Meetings:	Management is participating in virtual investor meetings on September 11 – 14, 2023
Webcast:	https://journey.ct.events/view/d901ec90-604f-458e-8973-a36787a54f8e

A replay of the webcast will be archived on the Events page on the company’s website, www.motusgi.com and will be available for 90 days.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Troy Williams
LifeSci Advisors
(518) 221-0106
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$0.00
Daily Volume:	0

March 18, 2024 Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 22, 2024 Motus GI Announces Exercise of Warrants for $2.7 Million Gross Proceeds February 21, 2024 Motus GI Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract January 30, 2024 Motus GI Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation November 13, 2023 Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE